Skip to main content
. Author manuscript; available in PMC: 2021 Mar 30.
Published in final edited form as: Diabetes Obes Metab. 2020 Jul 29;22(11):2045–2054. doi: 10.1111/dom.14121

FIGURE 2.

FIGURE 2

Effects of exenatide extended release (ER) treatment on glycated haemoglobin (HbA1c) levels. A, HbA1c levels in the two treatment arms at each study visit. There was a significant reduction in the HbA1c level in the exenatide ER group at 12 weeks (P = 0.045) and the levels were significantly different from the placebo group (P = 0.01). However, at 24 weeks, the differences between the groups were not statistically significant (P = 0.08). B, In those with a detectable level of C-peptide (C-pep+) at baseline (C-peptide ≥0.017 nmol/L), there was a significant reduction, compared to baseline, in the HbA1c level at 12 weeks (P = 0.0025) but not in those with undetectable C-peptide levels (C-pep−; C-peptide < 0.017 nmol/L). The treatment changes in each subgroup taken from the linear mixed model are shown. All data shown are from the linear mixed model (mean ± 95% confidence interval)